Generation Bio Co., a biotechnology company focused on T cell-driven autoimmune diseases, reported a net loss of $20.9 million for the quarter ended June 30, 2025, compared to a net loss of $20.4 million in the same period in 2024. General and administrative expenses decreased to $7.7 million from $9.5 million year-over-year. The company's cash balance stood at $141.4 million as of June 30, 2025. In a significant operational update, Generation Bio entered a memorandum of understanding to settle a litigation case with the landlord of a Waltham, MA facility. This settlement involves a lump-sum payment of $31 million and will extinguish a lease liability of $58 million in the third quarter of 2025. Additionally, Generation Bio is undergoing a strategic restructuring that will result in a 90% workforce reduction, including its research and development organization, as part of a review process to explore strategic alternatives. The company recently announced new data on its cell-targeted lipid nanoparticle system, demonstrating successful siRNA delivery to T cells in non-human primates.